Baseline characteristics of the external validation population and according to all-cause mortality and upper quartile of MR-proADM.

<p>¹GFR<60ml/min.</p><p>²Long-term use of bronchodilatators or steroids.</p><p>Abbreviations: GFR = glomerular filtration rate, SAVR = surgical aortic valve replacement, CABG = coronary artery bypass grafting, MI = myocardial infarction, NYHA = New York Heart Association, COPD = chronic obstructive pulmonary disease, BMI = body mass index, CAD = coronary artery disease.</p><p>Baseline characteristics of the external validation population and according to all-cause mortality and upper quartile of MR-proADM.</p

Procedural complications of the external validation cohort according to all-cause mortality and upper quartile of MR-proADM.

<p>Procedural complications of the external validation cohort according to all-cause mortality and upper quartile of MR-proADM.</p

Baseline characteristics of the derivation study population according to all-cause mortality and upper quartile of MR-proADM.

<p>¹GFR<60ml/min.</p><p>²Long-term use of bronchodilatators or steroids.</p><p>Abbreviations: GFR = glomerular filtration rate, SAVR = surgical aortic valve replacement, CABG = coronary artery bypass grafting, MI = myocardial infarction, NYHA = New York Heart Association, COPD = chronic obstructive pulmonary disease, BMI = body mass index, CAD = coronary artery disease.</p><p>Baseline characteristics of the derivation study population according to all-cause mortality and upper quartile of MR-proADM.</p

Clinical model enhancement by addition of MR-proADM.

<p><b>Risk assessment plot for the reference (EuroSCORE II, dashed lines) and biomarker-enhanced (solid line) model for 1-year mortality;</b> 1-specificity versus calculated risk for those with the event and sensitivity versus calculated risk for those without events are shown.</p

Procedural complications of the derivation patient population according to all-cause mortality and upper quartile of MR-proADM.

<p>Procedural complications of the derivation patient population according to all-cause mortality and upper quartile of MR-proADM.</p

Longitudinal trajectories of MR-proADM and CRP at post-interventional day 1–3 following TAVR.

<p>(A) Median and interquartile range of biomarkers in patients after TAVR according to postoperative mortality. (B) Individual trajectories of MR-proADM and CRP with LOWESS smoothing following TAVR.</p

Reclassification and calibration indices of the MR-proADM-enhanced model as compared to commonly used risk schmes (EuroSCORE II).

<p>Abbreviations: LRT = liklehood ratio test, IDI = integrated discrimination improvement, NRI = net reclassification index.</p><p>Reclassification and calibration indices of the MR-proADM-enhanced model as compared to commonly used risk schmes (EuroSCORE II).</p

RP-proportional hazards model with 3 dfs.

<p>Discriminatory ability of biomarker-enhanced models compared to existing risk schemes (EuroSCORE II) and proBNP.</p

Validation of the RP-derived PI.

<p><b>Solid lines: Kaplan-Meier survival curves in two prognostic groups (upper and lower quartiles of predicted risk) in the validation cohort.</b> Dashed lines: RP mean survival functions in the same prognostic groups of the validation cohort by the model fit to the derivation cohort.</p

Mortality rates of patients receiving TAVR, grouped by upper quartile of MR-proADM and EuroSCORE II.

<p>(A) Hazard rates. (B) Cumulative hazard rates. (C) Cumulative survival probabilities. (D) Hazard ratio (ES II = EuroSCORE II).</p